Lin Qiaoya, Huang Huang, Chen Juan, Zheng Gang
Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Methods Mol Biol. 2016;1444:153-66. doi: 10.1007/978-1-4939-3721-9_14.
Imaging has become an indispensable tool in both clinical medicine and preclinical sciences. It enables doctors to locate sites of cancer/disease, track drug delivery, and guide operative planning, thus enhancing the treatment efficacy. Recently, we developed a multimodal theranostic lipid nanoparticles, named HPPS(NIR)-chol-siRNA with its built-in near-infrared (NIR) fluorescent probe core as a useful surrogate for tracking small interfering RNA (siRNA) delivery. By using the image co-registration of computed tomography (CT) and fluorescence molecular tomography (FMT), we achieved noninvasive assessment and treatment planning of siRNA delivery into the orthotopic tumor, thus enabling efficacious RNA interference (RNAi) therapy. In this chapter, we introduce this method to illustrate the use of CT-FMT co-registration for tracking drug delivery and guiding treatment planning in vivo.
成像已成为临床医学和临床前科学中不可或缺的工具。它使医生能够定位癌症/疾病部位、追踪药物递送并指导手术规划,从而提高治疗效果。最近,我们开发了一种多模态诊疗脂质纳米颗粒,名为HPPS(NIR)-chol-siRNA,其内置近红外(NIR)荧光探针核心,可作为追踪小干扰RNA(siRNA)递送的有用替代物。通过使用计算机断层扫描(CT)和荧光分子断层扫描(FMT)的图像配准,我们实现了对原位肿瘤中siRNA递送的无创评估和治疗规划,从而实现了有效的RNA干扰(RNAi)治疗。在本章中,我们介绍这种方法,以说明CT-FMT配准在体内追踪药物递送和指导治疗规划中的应用。